PedAM
Pediatric Disease Annotations & Medicines
| capillary leak syndrome | ||||
| Disease ID | 701 |
|---|---|
| Disease | capillary leak syndrome |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:8) HP:0002615 | Low blood pressure | 4 HP:0000969 | Dropsy | 3 HP:0100598 | Pulmonary oedema | 2 HP:0000083 | Renal insufficiency | 1 HP:0001919 | Acute renal failure | 1 HP:0002202 | Pleural effusion | 1 HP:0001945 | Fever | 1 HP:0012398 | Peripheral edema | 1 |
| Disease ID | 701 |
|---|---|
| Disease | capillary leak syndrome |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:3) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:8) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0343084 | acitretin | D017255 | 55079-83-9 | capillary leak syndrome | MESH:D019559 | marker/mechanism | 14746632 | ||
| C0343084 | aldesleukin | C082598 | 110942-02-4 | capillary leak syndrome | MESH:D019559 | marker/mechanism | 11219485 | ||
| C0343084 | bortezomib | D000069286 | - | capillary leak syndrome | MESH:D019559 | marker/mechanism | 20150504 | ||
| C0343084 | clofarabine | C068329 | 123318-82-1 | capillary leak syndrome | MESH:D019559 | marker/mechanism | 20057324 | ||
| C0343084 | cisplatin | D002945 | 15663-27-1 | capillary leak syndrome | MESH:D019559 | marker/mechanism | 11822767 | ||
| C0343084 | gemcitabine | C056507 | 103882-84-4 | capillary leak syndrome | MESH:D019559 | marker/mechanism | 11822767 | ||
| C0343084 | piroxicam | D010894 | 36322-90-4 | capillary leak syndrome | MESH:D019559 | marker/mechanism | 14682198 | ||
| C0343084 | sirolimus | D020123 | 53123-88-9 | capillary leak syndrome | MESH:D019559 | marker/mechanism | 10328196 | ||
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D019559 | clolar | clofarabine | 20MG/20ML (1MG/ML) | INJECTABLE;IV (INFUSION) | Prescription | AP | Yes | Yes |
| MESH:D019559 | rapamune | sirolimus | 1MG/ML | SOLUTION;ORAL | Prescription | None | Yes | Yes |
| MESH:D019559 | rapamune | sirolimus | 1MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D019559 | velcade | bortezomib | 3.5MG/VIAL | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D019559 | 12/28/2004 | clolar | clofarabine | Relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens | Labeling for patients 1 to 21 years old. This use is based on the induction of complete responses Randomized trials demonstrating increased survival or other clinical benefit have not been conducted Information on dose, PK parameters, and AE profihe | Labeling | B | - | - | - | Genzyme | 07/14/2004 | FALSE' |
| MESH:D019559 | 11/3/2005 | rapamune | sirolimus | Prophylaxis of organ rejection in patients undergoing renal transplants | Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric ( | Labeling | B | - | - | - | Wyeth | 11/17/2004 | FALSE' |
| MESH:D019559 | 11/3/2005 | rapamune | sirolimus | Prophylaxis of organ rejection in patients undergoing renal transplants | Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric ( | Labeling | B | - | - | - | Wyeth | 11/17/2004 | FALSE' |
| MESH:D019559 | 09/14/2015 | velcade | bortezomib | Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Effectiveness in pediatric patients with relapsed pre-B ALL has not been established. The activity and safety of Velcade in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies. There were 140 patients with ALL or LL enrolled and evaluated for safety. No new safety concerns were observed | Labeling | B | - | - | - | Millennium Pharmaceuticals, Inc. | - | FALSE |